PRELIMINARY NOTE The unaudited condensed Consolidated Financial Statements for the three-month period ended March 31, 2023, included herein, have been prepared in. | May 4, 2023
- Aim is to develop gamma delta (?d) T-cell receptor (TCR)-based immunotherapies for solid tumors - Ph1/2 update on lead product GDT002 as well as nomination of second pipeline program